Pfizer Inks Global License to Genomatix Software and Databases

AnnArbor, MI, (PresseBox) - Genomatix Software, Inc. the US branch of Munich (Germany) based Genomatix Software GmbH, announced that it has reached an agreement with Pfizer Pharmaceuticals to provide Genomatix software and data content to Pfizer sites across the globe. The Genomatix tools licensed by Pfizer are designed to show how genes are regulated at a molecular level, and Pfizer scientists will use the software and data content to help understand the molecular basis of how their potential drug targets may be co-regulated with other important targets, producing potential desirable or unwanted side-effects.

"Adding Genomatix to Pfizer's existing genomics software capabilities was a natural choice." said Peter Grant, CEO of Genomatix Software, Inc. "Our broad set of capabilities are a good compliment to those that Pfizer already has in house. We are pleased to be a part of Pfizer's significant effort in molecular genomics. We believe our tools will provide a great value to their research effort, but the proof is always in the results. Now the fun really begins!" he concluded.

Genomatix Software GmbH

Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Core competences at Genomatix are annotation driven microarray analysis, regulatory network and pathway mining, and promoter analysis on sequence level. More information is available from http://www.genomatix.de

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.